CEO turned informant: How the FDA built a case against executives promising cheap medications

CNBCmarkets2026-11-18T21:07:14Z
The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.
PublisherCNBC
Categorymarkets
Published2026-11-18T21:07:14Z
Indexed9h ago
Read the full article at CNBC →

More from CNBC

Latest in markets

FinancePulse indexes headlines and short summaries from 20 institutional publishers. This page does not republish the full article — all rights belong to CNBC.